We focus on plasma-derived protein therapeutics for treatment of individuals with rare diseases and unmet medical needs.
Our proprietary platform technology and know-how allow us to extract and purify injectable protein therapeutics from human plasma.
Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis.
The allogeneic transplantation of hematopoietic cells (HCT) is a well-established treatment for hematologic diseases that cannot be cured with conventional treatments.The most common life-threatening complication is Graft Versus Host Disease (GVHD).